BFEC
INO icon

Benjamin F. Edwards & Company’s Inovio Pharmaceuticals INO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-118
Closed -$11K – 1734
2020
Q1 		$11K Buy
+118
New +$7.28K ﹤0.01% 1224

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Benjamin F. Edwards & Company's INO Position: Q2 2020 in Review

Benjamin F. Edwards & Company sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 118 shares — an estimated $11K sold.

Benjamin F. Edwards & Company first reported a position in INO in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

  • Benjamin F. Edwards & Company reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 118 Inovio Pharmaceuticals shares in Q2 2020, an estimated $11K.
  • Benjamin F. Edwards & Company first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Inovio Pharmaceuticals position peaked at $11K in Q1 2020.
  • 214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2020, filed 14 Aug 2020.